Skip to main content
SpringerLink
Log in

Antiasthmatic Drug Delivery in Children

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Asthma therapy can be administered to children via a number of routes, including oral, inhaled (via a multiplicity of devices), rectal, intravenous, subcutaneous, and intramuscular. The inhaled route is used most often. This can reduce, but never eliminate, systemic absorption. Swallowed aerosolized medication is subject to hepatic first-pass metabolism, but this metabolic route is bypassed by the drug impacting on the airway, including the pharynx.

Although there are a large number of studies from a laboratory setting about drug deposition characteristics, there is very little evidence from community-based studies about what families think actually works well in the everyday treatment of the child. However, it is clear that altering the inhaler device can result in marked changes in the dose administered, and any such change should be part of a review of the dose of prescribed medication. Nebulizers are being used much less frequently, and in particular, all but the most severe exacerbations can be treated at least as effectively with equivalent dosages of β2-adrenoceptor agonists from a large volume spacer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Agertoft L, Pederson S. Influence of spacer device on drag delivery to children with asthma. Arch Dis Child 1994; 71: 217–9

    Article  PubMed  CAS  Google Scholar 

  2. Mitchell JP, Nagel MW. In vitro performance testing of three small volume-holding chambers under conditions that correspond with use by infants and small children. J Aerosol Med 1997; 10: 341–9

    Article  PubMed  CAS  Google Scholar 

  3. Kamps AW, van Ewijk B, Roorda RJ, et al. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 2000; 29: 39–42

    Article  PubMed  CAS  Google Scholar 

  4. Ramsdell JW, Klinger NM, Ekholm BP, et al. Safety of long-term treatment with HFA albuterol. Chest 1999; 115: 945–51

    Article  PubMed  CAS  Google Scholar 

  5. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorcarbon beclamethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104: S258–67

    Article  PubMed  CAS  Google Scholar 

  6. Partridge MR, Woodcock AA, Sheffer AL, et al. Chlorofluorocarbon-free inhalers: are we ready for the change? Eur Respir J 1998; 11: 1006–8

    Article  PubMed  CAS  Google Scholar 

  7. Barry PW, O’Callaghan C. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. Eur Respir J 1997; 10: 1345–8

    Article  PubMed  CAS  Google Scholar 

  8. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients’ compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154: 1349–52

    Article  PubMed  CAS  Google Scholar 

  9. Wildhaber JH, Janssens HM, Pierart F, et al. High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000; 29: 389–93

    Article  PubMed  CAS  Google Scholar 

  10. Dempsey OJ, Wilson AM, Coutie WJ, et al. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 1999; 116: 935–40

    Article  PubMed  CAS  Google Scholar 

  11. Taylor AV, Laoprasert N, Zimmerman D, et al. Adrenal suppression secondary to inhaled fluticasone propionate. Ann Allergy Asthma Immunol 1999; 83: 68–70

    Article  PubMed  CAS  Google Scholar 

  12. Todd G, Dunlop K, McNaboe J, et al. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348: 27–9

    Article  PubMed  CAS  Google Scholar 

  13. Brutsche MH, Brutsche JC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556–61

    Article  PubMed  CAS  Google Scholar 

  14. Doull IJ, Campbell MJ, Holgate ST. Duration of growth suppressive effects of regular inhaled corticosteroids. Arch Dis Child 1998; 78: 172–3

    Article  PubMed  CAS  Google Scholar 

  15. Crowley S, Hindmarsh PC, Matthews DR, et al. Growth and the growth hormone axis in prepubertal children with asthma. J Pediatr 1995; 126: 297–303

    Article  PubMed  CAS  Google Scholar 

  16. James RW, Masters IB. Single breath versus panting technique in salbutamol delivery through a 750 ml spacing device. Pediatr Pulmonol 1990; 8: 263–7

    Article  PubMed  CAS  Google Scholar 

  17. British Thoracic Society. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52 Suppl. 1: S1–24

    Google Scholar 

  18. Bisgaard H. Future options for aerosol delivery to children. Allergy 1999; 54 Suppl. 49: 97–103

    Article  PubMed  Google Scholar 

  19. Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax 1997; 52: 686–9

    Article  PubMed  CAS  Google Scholar 

  20. Zar HJ, Weinberg EG, Binns HJ, et al. Lung deposition of aerosol: a comparison of different spacers. Arch Dis Child 2000; 82: 495–8

    Article  PubMed  CAS  Google Scholar 

  21. Zar HJ, Brown G, Donson H, et al. Home-made spacers for bronchodilator therapy in children with acute asthma: a randomised trial. Lancet 1999; 354: 979–82

    Article  PubMed  CAS  Google Scholar 

  22. Bisgaard H. A metal aerosol holding chamber devised for young children with asthma. Eur Respir J 1995; 8: 856–60

    Article  PubMed  CAS  Google Scholar 

  23. Janssens HM, Devadason SG, Hop WC, et al. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. Eur Respir J 1999; 13: 787–91

    Article  PubMed  CAS  Google Scholar 

  24. Everard ML, Devadason SG, Summers QA, et al. Factors affecting total and ‘respirable’ dose delivered by a salbutamol metered dose inhaler. Thorax 1995; 50: 746–9

    Article  PubMed  CAS  Google Scholar 

  25. O’Callaghan C, Lynch J, Cant M, et al. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax 1993; 48: 603–6

    Article  PubMed  Google Scholar 

  26. Pierart F, Wildhaber JH, Vrancken I, et al. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999; 13: 673–8

    Article  PubMed  CAS  Google Scholar 

  27. Janssens HM, Heijnen EMEW, De Jong VM, et al. Aerosol delivery from spacers in wheezy infants: a daily life study. Eur Respir J 2000; 16: 850–6

    Article  PubMed  CAS  Google Scholar 

  28. Parkin PC, Saunders NR, Diamond SA, et al. Randomised trial spacer v nebuliser for acute asthma. Arch Dis Child 1995; 72: 239–40

    Article  PubMed  CAS  Google Scholar 

  29. Kerem E, Levison H, Schuh S, et al. Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. J Pediatr 1993; 123: 313–7

    Article  PubMed  CAS  Google Scholar 

  30. Dewar AL, Stewart A, Cogswell JJ, et al. A randomised controlled trial to assess the relative benefits of large volume spacers to treat acute asthma in hospital. Arch Dis Child 1999; 80: 421–3

    Article  PubMed  CAS  Google Scholar 

  31. Cates CJ, Rowe BH. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma: a systematic review of randomised controlled trials (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2001

    Google Scholar 

  32. Rubilar L, Castro-Rodriguez JA, Girardi G. Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age. Pediatric Pulmonol 2000; 29: 1–7

    Article  Google Scholar 

  33. Mandelberg A, Tsehori S, Houri S, et al. Is nebulized aerosol treatment necessary in the pediatric emergency department: comparison with metal spacer device for metered-dose inhaler. Chest 2000; 117: 1309–13

    Article  PubMed  CAS  Google Scholar 

  34. Amirav I, Newhouse MT. Metered-dose inhaler accessory devices in acute asthma: efficacy and comparison with nebulizers; a literature review. Arch Pediatr Adolesc Med 1997; 151: 876–82

    Article  PubMed  CAS  Google Scholar 

  35. Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulizer or pressurised metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135: 28–33

    Article  PubMed  CAS  Google Scholar 

  36. Wildhaber JH, Devadason SG, Hayden MJ, et al. Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers. Pediatr Pulmonol 1997; 23: 212–6

    Article  PubMed  CAS  Google Scholar 

  37. Powell CVE, Maskell GR, Marks MK, et al. Successful implementation of spacer treatment guideline for acute asthma. Arch Dis Child 2001; 84: 142–6

    Article  PubMed  CAS  Google Scholar 

  38. O’Callaghan C, Barry P. Asthma drug delivery devices for children: it may be time to adopt a common strategy to simplify treatment. BMJ 2000; 320: 664–5

    Article  PubMed  Google Scholar 

  39. Chuffart AA, Sennhauser FH, Wildhaber JH. Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers. Swiss Med Wkly 2001; 131: 14–8

    PubMed  CAS  Google Scholar 

  40. National Institute for Clinical Excellence. Guidance for the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. London: National Institute for Clinical Excellence, 2000 Aug. Technology Appraisal Guidance No. 10

    Google Scholar 

  41. Newman SP, Moren F, Trofast E, et al. Deposition and clinical efficacy of terbutaline sulphate from turbuhaler, a new multi-dose powder inhaler. Eur Respir J 1989; 2: 247–52

    PubMed  CAS  Google Scholar 

  42. Wildhaber JH, Devadason SG, Wilson JM, et al. Lung deposition of budesonide from turbuhaler in asthmatic children. Eur J Pediatr 1998; 157: 1017–22

    Article  PubMed  CAS  Google Scholar 

  43. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a turbuhaler. Arch Dis Child 1990; 65: 308–19

    Article  PubMed  CAS  Google Scholar 

  44. Everard ML, Devadason SG, LeSoeuf PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a turbuhaler. Respir Med 1997; 91: 624–8

    Article  PubMed  CAS  Google Scholar 

  45. Bisgaard H, Pedersen S, Nikander K. Use of budesonide turbuhaler in young children suspected of asthma. Eur Respir J 1994; 7: 740–2

    Article  PubMed  CAS  Google Scholar 

  46. Lipworth BJ, Clark DJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulm Pharmac Ther 1997; 10: 211–4

    Article  CAS  Google Scholar 

  47. Toogood JH, White FA, Baskerville JC, et al. Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the turbuhaler dry powder inhaler. J Allergy Clin Immunol 1997; 99: 186–93

    Article  PubMed  CAS  Google Scholar 

  48. Ruggins NR, Milner AD, Swarbrick A. An assessment of a new breath actuated inhaler device in acutely wheezy children. Arch Dis Child 1993; 68: 477–80

    Article  PubMed  CAS  Google Scholar 

  49. Melchor R, Biddiscombe MF, Mak VHF, et al. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstructions. Thorax 1993; 48: 506–11

    Article  PubMed  CAS  Google Scholar 

  50. Toogood JH, Baskerville J, Jennings B, et al. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1984; 129: 723–9

    PubMed  CAS  Google Scholar 

  51. The Nebuliser Project Group of the British Thoracic Society Standards of Care Committee. Current best practice for nebuliser treatment. Thorax 1997; 52 Suppl. 2: S1–106

    Google Scholar 

  52. Kendrick AH, Smith EC, Wilson RSE. Selecting and using nebuliser equipment. Thorax 1997; 52 Suppl. 2: S92–100

    Article  PubMed  Google Scholar 

  53. Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest 1994; 106: 1788–93

    Article  PubMed  CAS  Google Scholar 

  54. Barry PW, O’Callaghan C. The output of budesonide from nebulisers. J Allergy Clin Immunol 1998; 102: 321–2

    Article  PubMed  CAS  Google Scholar 

  55. Faurisson F, Dessanges JF, Grimfeld A, et al. Nebulizer performance: AFLM study. Respiration 1995; 62 Suppl. 1: 13–8

    Article  PubMed  Google Scholar 

  56. Gregson RK, Warner JO, Radford M. Assessment of the continued supervision and asthma management knowledge of patients possessing home nebulizers. Respir Med 1995; 89: 487–93

    Article  PubMed  CAS  Google Scholar 

  57. Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993; 68: 356–9

    Article  PubMed  CAS  Google Scholar 

  58. Zorc JJ, Pusic MV, Ogborn CJ, et al. Ipratropium bromide added to asthma treatment in the paediatric emergency department. Pediatrics 1999; 103: 748–52

    Article  PubMed  CAS  Google Scholar 

  59. Ducharme FM, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma. J Pediatr 1998; 133: 479–85

    Article  PubMed  CAS  Google Scholar 

  60. Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med 1997; 29: 205–11

    Article  PubMed  CAS  Google Scholar 

  61. Osmond MH, Klassen TP. Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis. Acad Emerg Med 1995; 2: 651–6

    Article  PubMed  CAS  Google Scholar 

  62. Browne GJ, Penna AS, Phung X, et al. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. Lancet 1997; 349: 301–5

    Article  PubMed  CAS  Google Scholar 

  63. Godden CW, Campbell MJ, Hussey M, et al. Double blind placebo controlled trial of nebulised budesonide for croup. Arch Dis Child 1997; 76: 155–8

    Article  PubMed  CAS  Google Scholar 

  64. Klassen TP, Feldman ME, Watters LK, et al. Nebulized budesonide for children with mild-to-moderate croup. N Engl J Med 1994; 331: 285–9

    Article  PubMed  CAS  Google Scholar 

  65. Geelhoed GC, MacDonald WBG. Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg. Pediatr Pulmonol 1995; 20: 362–8

    Article  PubMed  CAS  Google Scholar 

  66. Tasche MJA, Uijen JHJM, Bernsen RMD, et al. Inhaled sodium cromoglycate (SCG) as maintenance therapy in children with asthma: a systematic review. Thorax 2000; 55: 913–20

    Article  PubMed  CAS  Google Scholar 

  67. O’Driscoll BR, Ruffles SP, Ayres JG, et al. Long term treatment of severe asthma with subcutaneous terbutaline. Br J Dis Chest 1988; 82: 360–7

    Article  PubMed  Google Scholar 

  68. Ayres JG, Miles JF, Barnes PJ. Brittle asthma. Thorax 1998; 53: 235–6

    Article  Google Scholar 

  69. Bremont F, Moisan V, Dutau G. Continuous subcutaneous infusion of beta-2 agonists in infantile asthma. Pediatr Pulmonol 1992; 12: 81–3

    Article  PubMed  CAS  Google Scholar 

  70. Payne D, Balfour-Lynn I, Biggart E, et al. Subcutaneous terbutaline in children with severe chronic asthma. Thorax 2000; 55 Suppl. 3: A55

    Google Scholar 

  71. Veeraghavan S, Sharma OP. Parenteral triamcinolone acetonide: an alternative corticosteroid for the treatment of asthma. Curr Opin Pulm Med 1998; 4: 31–5

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Brompton Hospital, London, UK

    Elizabeth Biggart

  2. Imperial School of Medicine, National Heart and Lung Institute, and Royal Brompton Hospital, London, UK

    Andrew Bush

Authors
  1. Elizabeth Biggart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Bush
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Bush.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biggart, E., Bush, A. Antiasthmatic Drug Delivery in Children. Pediatr-Drugs 4, 85–93 (2002). https://doi.org/10.2165/00128072-200204020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204020-00002

Keywords

Search

Navigation